Northwire Canada EditionThursday, July 23, 2026
Sign inSubscribe
Northwire
⌕
PAT 0.250 +0.0% CCM 0.520 +0.0% SGN 0.245 −3.9% CNC 1.48 +0.7% PHNM 0.325 +0.0% LIO 0.150 −6.2% RIO 2.69 −3.6% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.63 +8.0% ALTA 0.170 −2.9% CLCH 1.15 +10.6% SCOT 2.05 −2.8% VCT 0.060 +0.0% BOL 0.080 +6.7% MCM 0.300 +0.0% PAT 0.250 +0.0% CCM 0.520 +0.0% SGN 0.245 −3.9% CNC 1.48 +0.7% PHNM 0.325 +0.0% LIO 0.150 −6.2% RIO 2.69 −3.6% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.63 +8.0% ALTA 0.170 −2.9% CLCH 1.15 +10.6% SCOT 2.05 −2.8% VCT 0.060 +0.0% BOL 0.080 +6.7% MCM 0.300 +0.0%
M&A / Property

Briacell selected for MSK's Therapeutics Accelerator

By The Northwire Desk — AI Analysis Aug 13, 2025 · 17:08 BCT · 0.99 Briacell Therapeutics Corp
BCT · Price

Executive Summary

  • Briacell Therapeutics Corp. has been selected for the Memorial Sloan Kettering Cancer Center (MSK) 2025 Therapeutics Accelerator Cohort program.
  • The partnership aims to accelerate the clinical development of Bria-OTS+, a next-generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer and prostate cancer.
  • Through the program, Briacell will gain access to MSK’s expertise and resources, including GMP manufacturing services, IND application preparation, and regulatory strategy support.

Key Details

  • Program: MSK Therapeutics Accelerator 2025 Cohort.
  • Target Asset: Bria-OTS+, described as a next-generation personalized off-the-shelf immunotherapy.
  • Indications: Metastatic breast cancer, prostate cancer, and other cancers.
  • Resources Access:
    • GMP manufacturing services.
    • Investigational New Drug (IND) application preparation.
    • Submission and regulatory strategy support.
  • Strategic Goal: To expedite the development of Bria-OTS+ and leverage MSK’s 135+ years of leadership in cancer research and treatment.

Notable Quotes

  • Dr. William V. Williams, President and CEO: "We are honoured to work with the scientific and clinical experts at MSK Therapeutics Accelerator. MSK's deep expertise in cancer therapy development and state-of-the-art resources make it an ideal partner to accelerate our personalized off-the-shelf immunotherapy platform."
  • Dr. Miguel Lopez-Lago, Chief Scientific Officer: "We believe Bria-OTS+ has the potential to transform cancer care, offering meaningful advances in efficacy and safety for thousands of patients. Our participation in this cohort program is yet another step towards achieving that vision."
Read the original news release →

More from Briacell Therapeutics Corp

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other